Antithrombotic therapy during pregnancy

Seminars in Perinatology

Volumn 25, Issue 3, 2001, Pages 165-169

  Chan, Wee S ^a,b,c   Chunilal, Sanjeev D ^a,b,c   Ginsberg, Jeffrey S ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b JOHN HUNTER HOSPITAL   (Australia)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG HALF LIFE; FEMALE; HIGH RISK PREGNANCY; HUMAN; MATERNAL MORBIDITY; MATERNAL MORTALITY; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0034980265     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/sper.2001.24899     Document Type: Conference Paper

References (48)

1. Use of antithrombotic agents during pregnancy
2. Antithrombotic therapy for venous thromboembolism
3. Maternal and fetal sequelae of anticoagulation during pregnancy
4. Risks of anticoagulant therapy in pregnant women with artificial heart valves
5. Anticoagulation of pregnant women with mechanical heart valves: A systemic review of the literature
6. Dose dependent fetal complications of warfarin therpay in pregnant women with mechanical heart valves
7. Growth until puberty after in-utero exposure to coumarins
8. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses
9. Heparin and low-molecular heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
10. Anticoagulants during pregnancy
11. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: A meta-analysis
12. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
13. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
14. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
15. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
16. Comparison of subcutaneous unfractionated heparin with a low molecular heparin (Frogman) in patients with venous thromboembolism and contraindications to coumarin
17. Osteoporotic fractures and recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
18. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry
19. Heparin effect on bone density
20. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study
21. Subcutaneous low-molecular-weight heparin compared with continuous heparin in the treatment of proximal vein thrombosis
22. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
23. Heparin therapy during pregnancy
24. Hemostasis in normal pregnancy
25. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis
26. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin
27. Effect of pregnancy on the relationship between concentration and anticoagulant action of heparin
28. Comparing the in-vivo response to heparin in the plasma of non-pregnant and pregnant women
29. Subcutaneous heparin therapy during pregnancy: A need for concern at the time of delivery
30. Low-molecular-weight-heparins
31. Low molecular weight heparin use in pregnancy: Issues of safety and practicality
32. Safety of low-molecular-weight heparin in pregnancy: A systematic review
33. Birth outcomes in pregnant women treated with low-molecular-weight heparin
34. A comparison of low-molecular-weight heparin with unfractionated heparin for active pulmonary embolism
35. Maternal cardiovascular adjustments to pregnancy
36. Renal physiology and disease in pregnancy
37. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy
38. Anti-activated Factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin
39. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
40. Changes in the pharmacokinetics of the low-molecular weight heparin enoxaparin sodium during pregnancy
41. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man
42. Low-dose aspirin to prevent preeclampsia in women at high risk
43. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women
44. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antipospholipid antibodies)
45. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
46. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement
47. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic mangement